What Stifel's 2026 women's health report means for Australia

In January 2026, Tim Opler — Managing Director of Stifel's healthcare investment banking group — published the first of three volumes on women's health. Volume I runs to 236 pages and traces the history of female well-being and gynecology from antiquity to the present. Volume II will cover reproduction. Volume III, expected later in 2026, will cover the future of women's health and current biopharma efforts. That third volume is the one most directly relevant to anyone building translation infrastructure in this category.

The headline is not the history. It is the source. A bulge-bracket healthcare investment bank has just dedicated a multi-volume research series to arguing that women's health has been systematically under-invested for centuries and is now entering a structural catch-up. That framing, coming from sell-side capital markets rather than from advocacy, changes how the category reads to institutional investors, strategic partners, and public funders.

The most quotable statistic in the report is drawn from the National Academies review summarised by Veronica Barcelona in 2025: from 2013 to 2023, only 8.8% of NIH research dollars went to women's health research, and basic knowledge about women's physiological, hormonal and chromosomal differences remains thin. Opler pairs this with the observation that conditions like PCOS, endometriosis, menopause and PMS receive investment far below their disease burden. The Australian numbers are worse — 3.3% of government research funding in 2023–24 — but the international benchmark gives Australian funders a peer comparison that travels.

The most strategically useful section, for a translation platform, is the chapter on female-predominant disease. Drawing on work led by Sarah Temkin at the NIH Office of Research on Women's Health, the report endorses a three-pillar framework: autoimmune conditions (where women are nearly 80% of patients with lupus, Sjögren's and rheumatoid arthritis), chronic debilitating conditions (fibromyalgia, migraine, ME/CFS, where women can be up to 90% of the patient population), and age-related and lifestyle conditions (Alzheimer's, osteoporosis). This is a defensible scope statement for a national women's health translation vehicle — one that moves beyond reproductive health without losing analytical discipline.

Opler is careful, and we share the caution: the bar for what counts as 'female predominant' has to be set with judgement, or the category stretches to the point of meaninglessness. But the principle is sound. Conditions that disproportionately affect women, present differently in women, or have been historically mis-attributed to psychological causes deserve a translation pathway calibrated to their actual biology and care economics. The report's long historical treatment of endometriosis — centuries of mis-diagnosis as hysteria before Sampson named it in 1925 — is a reminder of what the cost of that miscalibration looks like in practice.

For Australia, the practical implications are three. First, this is corroborating evidence — not a substitute for primary sources — that the unmet need and capital-market opportunity are real and recognised at the highest tiers of US healthcare finance. It belongs in MRFF readiness narratives alongside the National Academies report, Temkin et al. (2023), and the Australian-specific data on diagnostic delay and economic burden. Second, it sharpens the scope question every Australian translation vehicle in this space has to answer: how broadly does 'women's health' extend, and on what evidence? The Temkin framework is a credible answer. Third, Volume III will name companies, modalities and financings. When it lands, the Australian science base needs a rapid-response commentary ready — one that maps Australian research strengths to the global pipeline Opler will profile, and identifies the assets that belong in international deal flow rather than stranded between proof-of-concept and the evidence package institutional capital requires.

The deeper signal in Stifel's decision to publish three volumes on this topic is that the translation gap is now visible to the people who allocate capital. The countries that build the infrastructure to convert research into ventures will capture the value. The countries that do not will license their science elsewhere, pay full freight on the products that come back, and watch the expertise compound somewhere else.